DK1670823T3 - Kimært mhc-protein og oligomer deraf til specifik målretning - Google Patents

Kimært mhc-protein og oligomer deraf til specifik målretning

Info

Publication number
DK1670823T3
DK1670823T3 DK04768739.7T DK04768739T DK1670823T3 DK 1670823 T3 DK1670823 T3 DK 1670823T3 DK 04768739 T DK04768739 T DK 04768739T DK 1670823 T3 DK1670823 T3 DK 1670823T3
Authority
DK
Denmark
Prior art keywords
oligoms
chimaretic
specific targeting
mhc protein
mhc
Prior art date
Application number
DK04768739.7T
Other languages
English (en)
Inventor
Nikolai Franz Gregor Schwabe
Original Assignee
Proimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proimmune Ltd filed Critical Proimmune Ltd
Application granted granted Critical
Publication of DK1670823T3 publication Critical patent/DK1670823T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
DK04768739.7T 2003-10-06 2004-10-04 Kimært mhc-protein og oligomer deraf til specifik målretning DK1670823T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0323324A GB2408507B (en) 2003-10-06 2003-10-06 Chimeric MHC protein and oligomer thereof for specific targeting
PCT/GB2004/004199 WO2005035567A1 (en) 2003-10-06 2004-10-04 Chimeric mhc protein and oligomer thereof for specific targeting

Publications (1)

Publication Number Publication Date
DK1670823T3 true DK1670823T3 (da) 2013-12-16

Family

ID=29415574

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04768739.7T DK1670823T3 (da) 2003-10-06 2004-10-04 Kimært mhc-protein og oligomer deraf til specifik målretning

Country Status (5)

Country Link
US (1) US20050074848A1 (da)
EP (1) EP1670823B1 (da)
DK (1) DK1670823T3 (da)
GB (1) GB2408507B (da)
WO (1) WO2005035567A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
US9457070B2 (en) * 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
ES2516690T5 (es) 2005-06-07 2017-11-21 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad de serina proteasa y su uso en métodos y composiciones para el tratamiento de rechazo de injertos y promoción de supervivencia de injertos
EP1982176A1 (en) * 2006-01-30 2008-10-22 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
GB2442048B (en) * 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US10722562B2 (en) * 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11585806B2 (en) 2014-06-13 2023-02-21 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
NZ758485A (en) 2017-04-27 2024-02-23 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
AU3220593A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
US5861156A (en) * 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
EP0938571B8 (en) * 1996-10-28 2008-07-02 University of Lausanne Method for the oligomerisation of peptides
US6232445B1 (en) * 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
AU765378B2 (en) * 1998-02-19 2003-09-18 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US7264965B2 (en) * 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
GB2339782A (en) * 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
AU3693000A (en) * 1999-01-29 2000-08-18 Licentia Ltd Platelet-derived growth factor/vascular endothelial growth factor-like growth factor h, and uses thereof
EP1274852A2 (en) * 2000-04-12 2003-01-15 University Of Rochester Targeted vaccine delivery systems
AU2001271273A1 (en) * 2000-05-24 2001-12-03 Ludwig Institute For Cancer Research Multicomponent conjugates which bind to target molecules and stimulate cell lysis
WO2002055992A2 (en) * 2001-01-12 2002-07-18 Becton Dickinson Co Intrinsically fluorescent, self-multimerizing mhc fusion proteins and complexes thereof
US20020082411A1 (en) * 2001-01-23 2002-06-27 Darrick Carter Immune mediators and related methods
US6811785B2 (en) * 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof

Also Published As

Publication number Publication date
WO2005035567A1 (en) 2005-04-21
GB0323324D0 (en) 2003-11-05
GB2408507A (en) 2005-06-01
US20050074848A1 (en) 2005-04-07
EP1670823A1 (en) 2006-06-21
EP1670823B1 (en) 2013-10-02
GB2408507B (en) 2005-12-14

Similar Documents

Publication Publication Date Title
DK1670823T3 (da) Kimært mhc-protein og oligomer deraf til specifik målretning
NO20053896D0 (no) System og fremgangsmate for automatisert malretting
DK1641822T3 (da) Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
IS8153A (is) Ónæmisbælandi efnasambönd og efnablöndur
IS7726A (is) Pyrazólólpyridín og aðferðir til þess að búa þau til og nota
DK1583542T3 (da) Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
DK1608762T3 (da) Forbedrede alphavirusreplikoner og hjælperkonstrukter
DK1475721T3 (da) Brugerautentificeringsfremgangsmåde og brugerautentificeringssystem
IS7369A (is) Aðferð og tæki til örflögunýmyndunar
NO20040640L (no) Anordning og fremgangsmate
DK1997809T3 (da) P38-inhibitorer og fremgangsmåder til anvendelse deraf
IS8458A (is) Fyrirtækjamatsbúnaður og fyrirtækjamatsforrit
IS8037A (is) P38-hindrar og aðferðir til notkunar þeirra
DK1519770T3 (da) Elektroporesisk indretning og indsprøjtningsapparat
NO20055778D0 (no) Folgesystem og assosiert fremgangsmate
IS8453A (is) Fyrirtækjamatsbúnaður og fyrirtækjamatsforrit
DK1620456T3 (da) Hla-a2 tumor-associerede antigen-peptider og præparater
NO20055173D0 (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
DK1511734T3 (da) Forbindelser, præparater og fremgangsmåder
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
DK1620551T3 (da) Phospholipase og fremgangsmåde til fremstilling deraf
NO20055708D0 (no) Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav
IS7960A (is) Samsetningar og aðferðir til þess að meðhöndla krabbamein með því að nota IGSF9 og LIV-1
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
IS8489A (is) Umritunarstillar og aðferðir þeirra